Literature DB >> 34031129

The Host Cellular Immune Response to Infection by Campylobacter Spp. and Its Role in Disease.

Sean M Callahan1, Carolina G Dolislager1, Jeremiah G Johnson1.   

Abstract

Campylobacter spp. are the leading cause of bacterium-derived gastroenteritis worldwide, impacting 96 million individuals annually. Unlike other bacterial pathogens of the gastrointestinal tract, Campylobacter spp. lack many of the classical virulence factors that are often associated with the ability to induce disease in humans, including an array of canonical secretion systems and toxins. Consequently, the clinical manifestations of human campylobacteriosis and its resulting gastrointestinal pathology are believed to be primarily due to the host immune response toward the bacterium. Further, while gastrointestinal infection is usually self-limiting, numerous postinfectious disorders can occur, including the development of Guillain-Barré syndrome, reactive arthritis, and irritable bowel syndrome. Because gastrointestinal disease likely results from the host immune response, the development of these postinfectious disorders may be due to dysregulation or misdirection of the same inflammatory response. As a result, it is becoming increasingly important to the Campylobacter field, and human health, that the cellular immune responses toward Campylobacter be better understood, including which immunological events are critical to the development of disease and the postinfectious disorders mentioned above. In this review, we collectively cover the cellular immune responses across susceptible hosts to Campylobacter jejuni infection, along with the tissue pathology and postinfectious disorders which may develop.

Entities:  

Keywords:  Campylobacter; gastrointestinal infection; immune response; infectious disease

Mesh:

Year:  2021        PMID: 34031129      PMCID: PMC8281273          DOI: 10.1128/IAI.00116-21

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  186 in total

1.  A bacterial toxin that controls cell cycle progression as a deoxyribonuclease I-like protein.

Authors:  M Lara-Tejero; J E Galán
Journal:  Science       Date:  2000-10-13       Impact factor: 47.728

Review 2.  Tissue-Resident Macrophage Ontogeny and Homeostasis.

Authors:  Florent Ginhoux; Martin Guilliams
Journal:  Immunity       Date:  2016-03-15       Impact factor: 31.745

3.  The Helical Shape of Campylobacter jejuni Promotes In Vivo Pathogenesis by Aiding Transit through Intestinal Mucus and Colonization of Crypts.

Authors:  Martin Stahl; Emilisa Frirdich; Jenny Vermeulen; Yuliya Badayeva; Xiaoxia Li; Bruce A Vallance; Erin C Gaynor
Journal:  Infect Immun       Date:  2016-11-18       Impact factor: 3.441

4.  Occurrence of Campylobacter jejuni in pets living with human patients infected with C. jejuni.

Authors:  Peter Damborg; Katharina E P Olsen; Eva Møller Nielsen; Luca Guardabassi
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

Review 5.  The double-edged role of neutrophil extracellular traps in inflammation.

Authors:  Maximilien Euler; Markus H Hoffmann
Journal:  Biochem Soc Trans       Date:  2019-12-20       Impact factor: 5.407

Review 6.  Campylobacter species and Guillain-Barré syndrome.

Authors:  I Nachamkin; B M Allos; T Ho
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

7.  Host-specific differences in the response of cultured macrophages to Campylobacter jejuni capsule and O-methyl phosphoramidate mutants.

Authors:  Sungwon Kim; Andrea Vela; Sara M Clohisey; Spiridoula Athanasiadou; Pete Kaiser; Mark P Stevens; Lonneke Vervelde
Journal:  Vet Res       Date:  2018-01-09       Impact factor: 3.683

Review 8.  Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.

Authors:  John Daly; Mattias Carlsten; Michael O'Dwyer
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

Review 9.  Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy.

Authors:  Thiago A Patente; Mariana P Pinho; Aline A Oliveira; Gabriela C M Evangelista; Patrícia C Bergami-Santos; José A M Barbuto
Journal:  Front Immunol       Date:  2019-01-21       Impact factor: 7.561

Review 10.  NOD Signaling and Cell Death.

Authors:  Valentin J Heim; Che A Stafford; Ueli Nachbur
Journal:  Front Cell Dev Biol       Date:  2019-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.